Company intelligence / Profile preview
AMAL Therapeutics
Geneva, Geneva, Switzerlandamaltherapeutics.com ↗
- Ownership
- Private
- Employees
- ~29
- Development stage
- Preclinical
01
Overview
AMAL Therapeutics develops first-in-class protein-based therapeutic vaccines using its proprietary KISIMA® platform. Its lead asset ATP128 targets metastatic colorectal cancer and has entered Phase Ib clinical trials both as a monotherapy and in combination with Boehringer Ingelheim’s anti-PD1 compound. Early data show strong preclinical efficacy and safety; the company retains full development rights to its lead candidate and platform. The company collaborates with Natera on biomarker-driven response assessment using Signatera MRD testing.
- Therapeutic areas
- Oncology
- Modalities
- Protein-based therapeutic vaccinespeptide/protein-based immunisation technology
- Industry
- Pharma
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Boehringer Ingelheim (parent company, co-developing/commercializing pipeline assets)Natera Inc. – partnership on use of Signatera MRD test in clinical trial for treatment response monitoring in stage IV CRC patients
Beyond the preview
Go deeper on AMAL Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMAL Therapeutics.